PL3679034T3 - Pochodne 1-(4-(izoksazol-5-ilo)-1h-pirazol-1-ilo)-2-metylo-propan-2-olu i związki pokrewne jako inhibitory il-7 i ifn-gamma do leczenia chorób autoimmunologicznych i przewlekłego zapalenia - Google Patents
Pochodne 1-(4-(izoksazol-5-ilo)-1h-pirazol-1-ilo)-2-metylo-propan-2-olu i związki pokrewne jako inhibitory il-7 i ifn-gamma do leczenia chorób autoimmunologicznych i przewlekłego zapaleniaInfo
- Publication number
- PL3679034T3 PL3679034T3 PL18762111.5T PL18762111T PL3679034T3 PL 3679034 T3 PL3679034 T3 PL 3679034T3 PL 18762111 T PL18762111 T PL 18762111T PL 3679034 T3 PL3679034 T3 PL 3679034T3
- Authority
- PL
- Poland
- Prior art keywords
- ilo
- isoxazol
- propan
- ifn
- pyrazole
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Transplantation (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17189652 | 2017-09-06 | ||
| PCT/EP2018/073993 WO2019048541A1 (en) | 2017-09-06 | 2018-09-06 | 1- (4- (ISOXAZOL-5-YL) -1H-PYRAZOL-1-YL) -2-METHYLPROPAN-2-OL DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF IL-17 AND IFN- GAMMA FOR THE TREATMENT OF AUTOIMMUNE DISEASES AND CHRONIC INFLAMMATION |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3679034T3 true PL3679034T3 (pl) | 2022-11-14 |
Family
ID=59799324
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL18762111.5T PL3679034T3 (pl) | 2017-09-06 | 2018-09-06 | Pochodne 1-(4-(izoksazol-5-ilo)-1h-pirazol-1-ilo)-2-metylo-propan-2-olu i związki pokrewne jako inhibitory il-7 i ifn-gamma do leczenia chorób autoimmunologicznych i przewlekłego zapalenia |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US11292788B2 (pl) |
| EP (2) | EP4074708A1 (pl) |
| JP (2) | JP2020532575A (pl) |
| KR (1) | KR20200069299A (pl) |
| CN (1) | CN111433202A (pl) |
| AU (1) | AU2018330633C1 (pl) |
| CA (1) | CA3074891A1 (pl) |
| CY (1) | CY1125514T1 (pl) |
| DK (1) | DK3679034T3 (pl) |
| ES (1) | ES2925538T3 (pl) |
| HR (1) | HRP20221042T1 (pl) |
| HU (1) | HUE059822T2 (pl) |
| IL (1) | IL273064B2 (pl) |
| LT (1) | LT3679034T (pl) |
| MA (1) | MA50069B1 (pl) |
| MD (1) | MD3679034T2 (pl) |
| MX (1) | MX2020002571A (pl) |
| PH (1) | PH12020500461A1 (pl) |
| PL (1) | PL3679034T3 (pl) |
| PT (1) | PT3679034T (pl) |
| RS (1) | RS63532B1 (pl) |
| SG (1) | SG11202001409UA (pl) |
| SI (1) | SI3679034T1 (pl) |
| SM (1) | SMT202200343T1 (pl) |
| UA (1) | UA126689C2 (pl) |
| WO (1) | WO2019048541A1 (pl) |
| ZA (1) | ZA202001179B (pl) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT3679034T (lt) * | 2017-09-06 | 2022-09-12 | Immunic Ag | 1-(4-(izoksazol-5-il)-1h-pirazol-1-il)-2-metilpropan-2-olio dariniai ir susiję junginiai, kaip il-7 ir ifn- gama inhibitoriai, skirti autoimuninių ligų ir lėtinių uždegimų gydymui |
| US20240368145A1 (en) | 2021-07-09 | 2024-11-07 | Immunic Ag | Methods for treating cancer |
| CN113683505A (zh) * | 2021-09-29 | 2021-11-23 | 厦门大华本安化工安全研究院有限公司 | 一种含氧代环丁基的羧酸酯类化合物的制备方法 |
| WO2023198873A1 (en) | 2022-04-14 | 2023-10-19 | Immunic Ag | Deuterated rorgamma/rorgammat inverse agonists |
| WO2023232870A1 (en) | 2022-05-31 | 2023-12-07 | Immunic Ag | Rorg/rorgt modulators for the treatment of virus infections like covid-19 |
| CN119192167B (zh) * | 2024-11-28 | 2025-03-21 | 英矽智能科技(上海)有限公司 | 一类抑制il-17的化合物 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2668183T3 (da) | 2011-01-28 | 2018-01-29 | 4Sc Discovery Gmbh | Hæmning af IL17 og IFN-gamma til behandling af autoimmun inflammation |
| CN103476771B (zh) | 2011-01-28 | 2015-12-23 | 4Sc探索有限责任公司 | 用于治疗自身免疫炎症的IL17和IFN-γ抑制 |
| LT3679034T (lt) * | 2017-09-06 | 2022-09-12 | Immunic Ag | 1-(4-(izoksazol-5-il)-1h-pirazol-1-il)-2-metilpropan-2-olio dariniai ir susiję junginiai, kaip il-7 ir ifn- gama inhibitoriai, skirti autoimuninių ligų ir lėtinių uždegimų gydymui |
-
2018
- 2018-09-06 LT LTEPPCT/EP2018/073993T patent/LT3679034T/lt unknown
- 2018-09-06 SI SI201830741T patent/SI3679034T1/sl unknown
- 2018-09-06 JP JP2020514532A patent/JP2020532575A/ja active Pending
- 2018-09-06 EP EP22176185.1A patent/EP4074708A1/en not_active Withdrawn
- 2018-09-06 MA MA50069A patent/MA50069B1/fr unknown
- 2018-09-06 HU HUE18762111A patent/HUE059822T2/hu unknown
- 2018-09-06 KR KR1020207009871A patent/KR20200069299A/ko not_active Ceased
- 2018-09-06 SG SG11202001409UA patent/SG11202001409UA/en unknown
- 2018-09-06 US US16/644,581 patent/US11292788B2/en active Active
- 2018-09-06 DK DK18762111.5T patent/DK3679034T3/da active
- 2018-09-06 SM SM20220343T patent/SMT202200343T1/it unknown
- 2018-09-06 HR HRP20221042TT patent/HRP20221042T1/hr unknown
- 2018-09-06 AU AU2018330633A patent/AU2018330633C1/en not_active Ceased
- 2018-09-06 WO PCT/EP2018/073993 patent/WO2019048541A1/en not_active Ceased
- 2018-09-06 MD MDE20200707T patent/MD3679034T2/ro unknown
- 2018-09-06 CA CA3074891A patent/CA3074891A1/en active Pending
- 2018-09-06 UA UAA202002206A patent/UA126689C2/uk unknown
- 2018-09-06 MX MX2020002571A patent/MX2020002571A/es unknown
- 2018-09-06 EP EP18762111.5A patent/EP3679034B1/en active Active
- 2018-09-06 RS RS20220796A patent/RS63532B1/sr unknown
- 2018-09-06 PT PT187621115T patent/PT3679034T/pt unknown
- 2018-09-06 PL PL18762111.5T patent/PL3679034T3/pl unknown
- 2018-09-06 CN CN201880058056.9A patent/CN111433202A/zh active Pending
- 2018-09-06 ES ES18762111T patent/ES2925538T3/es active Active
-
2020
- 2020-02-25 ZA ZA2020/01179A patent/ZA202001179B/en unknown
- 2020-03-04 IL IL273064A patent/IL273064B2/en unknown
- 2020-03-06 PH PH12020500461A patent/PH12020500461A1/en unknown
-
2022
- 2022-08-25 CY CY20221100574T patent/CY1125514T1/el unknown
- 2022-12-23 JP JP2022206807A patent/JP2023052060A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL289534A (en) | Parp1 inhibitors | |
| PL3710439T3 (pl) | Inhibitory kras g12c | |
| IL256056A (en) | Ezh2 inhibitors for treating lymphoma | |
| IL261721A (en) | Combinations of lsd1 inhibitors for use in the treatment of solid tumors | |
| PL3472153T3 (pl) | Pirymidyn-2-yloamino-1h-pirazole jako inhibitory lrrk2 do zastosowania w leczeniu zaburzeń neurodegeneracyjnych | |
| IL275948A (en) | History of H2-indazole as CDK4 and CDK6 inhibitors and their medical uses | |
| IL247841A0 (en) | Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders | |
| LT3768674T (lt) | Aminopirimidino dariniai kaip ctps1 inhibitoriai | |
| EP3432927A4 (en) | TRIPLE-SPECIFIC INHIBITORS FOR CANCER TREATMENT | |
| IL249895A0 (en) | 2-h-indazole derivatives as cyclin-dependent kinase (cdk) inhibitors and therapeutic uses thereof | |
| PL3157534T3 (pl) | Inhibitory acetylocholinesteraz w leczeniu stanów dermatologicznych | |
| EP3256218A4 (en) | Kdm1a inhibitors for the treatment of disease | |
| EA201591509A1 (ru) | Ингибиторы cdc7 | |
| PL3539961T3 (pl) | Policykliczne pochodne amidowe jako inhibitory CDK9 | |
| EP3174539A4 (en) | Inhibitors of bruton's tyrosine kinase | |
| IL279260A (en) | KDM1A inhibitors for the treatment of diseases | |
| PL3485890T3 (pl) | Inhibitory SGLT2 do leczenia zaburzeń metabolicznych u zwierząt psowatych | |
| ZA201605715B (en) | Cyclopropylamines as lsd1 inhibitors | |
| EP3206749A4 (en) | Use of cdk9 and brd4 inhibitors to inhibit inflammation | |
| IL283069A (en) | Methods for administering corticosteroids | |
| DK3679034T3 (da) | 1-(4-(isoxazol-5-yl)-1h-pyrazol-1-yl)-2-methylpropan-2-ol-derivater og dertilhørende forbindelser som il-7- og ifn-gamma-inhibitorer til behandling af autoimmunsygdomme og kronisk inflammation | |
| EA201790484A1 (ru) | Производные тетрагидрохинолина в качестве ингибиторов бромодомена | |
| IL263804A (en) | Wnt inhibitors for use in the treatment of fibrosis | |
| SG11201609335RA (en) | New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases | |
| PL3697399T3 (pl) | Środki terapeutyczne do zastosowania w leczeniu zespołu niespokojnych nóg |